I期临床-话题@MedSci

#I期临床#

570篇内容 | 7042人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653074, encodeId=7fed16530e4e2, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, objectType=article, longId=199310, objectId=a5e8199310d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5e8199310d0, replyNumber=0, likeNumber=90, createdTime=2020-08-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5e8199310d0, moduleTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5e8199310d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653071, encodeId=9d8816530e103, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=大麻素！或是治疗阿尔茨海默症的希望，FDA已批准开展I期临床试验, objectType=article, longId=199297, objectId=c09119929e48, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c09119929e48, replyNumber=0, likeNumber=92, createdTime=2021-01-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c09119929e48, moduleTitle=大麻素！或是治疗阿尔茨海默症的希望，FDA已批准开展I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c09119929e48)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653007, encodeId=c558165300e78, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始, objectType=article, longId=191296, objectId=4009191296a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4009191296a0, replyNumber=0, likeNumber=58, createdTime=2020-09-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4009191296a0, moduleTitle=重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4009191296a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653139, encodeId=e75a165313976, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet子刊：COVID-19 DNA候选疫苗INO-4800的I期临床，在所有患者中触发免疫原性, objectType=article, longId=204904, objectId=620a20490483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=620a20490483, replyNumber=0, likeNumber=58, createdTime=2021-09-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=620a20490483, moduleTitle=Lancet子刊：COVID-19 DNA候选疫苗INO-4800的I期临床，在所有患者中触发免疫原性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=620a20490483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653158, encodeId=0a541653158d9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：III期临床证实mRNA-1273疫苗有效率达94.1%, objectType=article, longId=206787, objectId=a50f206e879d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a50f206e879d, replyNumber=0, likeNumber=55, createdTime=2021-09-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a50f206e879d, moduleTitle=NEJM：III期临床证实mRNA-1273疫苗有效率达94.1%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a50f206e879d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653042, encodeId=80d3165304226, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切, objectType=article, longId=196105, objectId=041919610548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=041919610548, replyNumber=0, likeNumber=74, createdTime=2020-12-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=041919610548, moduleTitle=III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=041919610548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653089, encodeId=61e9165308925, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：贝利木单抗治疗活动性狼疮性肾炎III期临床获得成功, objectType=article, longId=200854, objectId=2372200854b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2372200854b6, replyNumber=0, likeNumber=59, createdTime=2021-08-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2372200854b6, moduleTitle=NEJM：贝利木单抗治疗活动性狼疮性肾炎III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2372200854b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653149, encodeId=117b165314929, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点, objectType=article, longId=205711, objectId=ced5205e1160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced5205e1160, replyNumber=0, likeNumber=63, createdTime=2021-08-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced5205e1160, moduleTitle=礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced5205e1160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653049, encodeId=2b531653049a0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NATURE：艾滋病候选长效药物I期临床：注射一次可维持半年, objectType=article, longId=196927, objectId=4ac719692e15, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ac719692e15, replyNumber=0, likeNumber=42, createdTime=2021-04-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ac719692e15, moduleTitle=NATURE：艾滋病候选长效药物I期临床：注射一次可维持半年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ac719692e15)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653124, encodeId=ed7216531249d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet Infect Dis：志贺氏菌属SF2a-TT15疫苗I期临床研究获得成功, objectType=article, longId=203273, objectId=23722032e30c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23722032e30c, replyNumber=0, likeNumber=74, createdTime=2021-10-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23722032e30c, moduleTitle=Lancet Infect Dis：志贺氏菌属SF2a-TT15疫苗I期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23722032e30c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653088, encodeId=13a81653088ab, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败, objectType=article, longId=200768, objectId=614b200e686d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=614b200e686d, replyNumber=0, likeNumber=62, createdTime=2020-09-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=614b200e686d, moduleTitle=Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=614b200e686d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653156, encodeId=0586165315600, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Brilacidin治疗COVID-19的II期临床试验，计划于下周开始, objectType=article, longId=206528, objectId=f96e206528c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f96e206528c2, replyNumber=0, likeNumber=0, createdTime=2021-09-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f96e206528c2, moduleTitle=Brilacidin治疗COVID-19的II期临床试验，计划于下周开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f96e206528c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653117, encodeId=ed54165311e58, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=中国批准国产阿尔茨海默症早诊示踪剂进入III期临床, objectType=article, longId=202931, objectId=45b2202931e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45b2202931e6, replyNumber=0, likeNumber=98, createdTime=2021-02-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45b2202931e6, moduleTitle=中国批准国产阿尔茨海默症早诊示踪剂进入III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45b2202931e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653015, encodeId=36a216530150e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效, objectType=article, longId=193033, objectId=b12819303320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12819303320, replyNumber=0, likeNumber=74, createdTime=2020-08-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12819303320, moduleTitle=II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b12819303320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653009, encodeId=c4561653009fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准, objectType=article, longId=191730, objectId=1f9c191e301a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f9c191e301a, replyNumber=0, likeNumber=70, createdTime=2020-06-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f9c191e301a, moduleTitle=亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f9c191e301a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653013, encodeId=ebcc16530139f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, objectType=article, longId=192391, objectId=50af192391d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50af192391d8, replyNumber=0, likeNumber=65, createdTime=2020-11-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50af192391d8, moduleTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50af192391d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653039, encodeId=8ec9165303982, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, objectType=article, longId=195932, objectId=08a71959323d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08a71959323d, replyNumber=0, likeNumber=57, createdTime=2020-09-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08a71959323d, moduleTitle=实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08a71959323d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653112, encodeId=f4e2165311293, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, objectType=article, longId=202599, objectId=ad7320259999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad7320259999, replyNumber=0, likeNumber=72, createdTime=2021-05-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad7320259999, moduleTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad7320259999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652993, encodeId=305b165299325, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=脑肿瘤一线治疗：VAL-083的II期临床试验即将开始, objectType=article, longId=188493, objectId=779818849367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=779818849367, replyNumber=0, likeNumber=129, createdTime=2020-04-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=779818849367, moduleTitle=脑肿瘤一线治疗：VAL-083的II期临床试验即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=779818849367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653030, encodeId=7008165303026, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=靶向Trop-2用于三阴性乳腺癌重磅ADC药物在中国启动II期临床, objectType=article, longId=194629, objectId=5ba51946297d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ba51946297d, replyNumber=0, likeNumber=0, createdTime=2020-11-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ba51946297d, moduleTitle=靶向Trop-2用于三阴性乳腺癌重磅ADC药物在中国启动II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ba51946297d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期

2020-08-24

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

大麻素！或是治疗阿尔茨海默症的希望，FDA已批准开展I期临床试验

2021-01-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始

2020-09-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet子刊：COVID-19 DNA候选疫苗INO-4800的I期临床，在所有患者中触发免疫原性

2021-09-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：III期临床证实mRNA-1273疫苗有效率达94.1%

2021-09-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切

2020-12-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：贝利木单抗治疗活动性狼疮性肾炎III期临床获得成功

2021-08-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点

2021-08-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NATURE：艾滋病候选长效药物I期临床：注射一次可维持半年

2021-04-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet Infect Dis：志贺氏菌属SF2a-TT15疫苗I期临床研究获得成功

2021-10-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败

2020-09-24

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Brilacidin治疗COVID-19的II期临床试验，计划于下周开始

2021-09-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

中国批准国产阿尔茨海默症早诊示踪剂进入III期临床

2021-02-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效

2020-08-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准

2020-06-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组

2020-11-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展

2020-09-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

拜耳Finerenone FIDELIO-DKD III期临床研究结果公布

2021-05-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

脑肿瘤一线治疗：VAL-083的II期临床试验即将开始

2020-04-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

靶向Trop-2用于三阴性乳腺癌重磅ADC药物在中国启动II期临床

2020-11-13

科室
- - 订阅+
  - 更多科室
工具
服务